论文部分内容阅读
目的:优选蟾酥中3种单体(蟾蜍灵、华蟾蜍精、脂蟾毒配基)体外抗癌最佳配伍。方法:采用均匀设计法分成7组给药,分别为丝裂霉素组及给药A-F组,分别作用于肺癌(H441)宫颈癌(Hela)和白血病(HL-60)细胞株,采用WST-8细胞计数试剂盒,评价对3种癌细胞的抑制作用,筛选蟾蜍灵、华蟾蜍精、脂蟾毒配基最佳配伍。对最佳配伍进行比较和验证试验。结果:与对照组比较,在肺癌(H441)和宫颈癌(Hela)细胞上A,B组抑制作用与丝裂霉素相当(P>0.05),在白血病(HL-60)细胞上A组抑制作用于丝裂霉素相当(P>0.05)。经多元统计分析,蟾蜍灵、华蟾蜍精、脂蟾毒配基最佳配伍组合为100,100,15μmol·L~(-1)。结论:应用均匀设计和体外抗癌作用评价相结合确定蟾酥中3种单体蟾蜍灵、华蟾蜍精、脂蟾毒配基最佳配伍的方法是可行的,验证实验表明,蟾蜍灵、华蟾蜍精、脂蟾毒配基最佳配伍体外抑制癌细胞的作用与丝裂霉素相当,略好于组合中的每个单体。
OBJECTIVE: To optimize the anticancer best compatibility of 3 monomers in Toadstool (Bufalin, Hua toad, and bursal toxin) in vitro. Methods: Homogeneous design was used to divide into 7 groups: Mitomycin group and AF group, which were respectively treated with HeLa and HL-60 cells of lung cancer (H441) 8 cell counting kit to evaluate the inhibitory effect on the three kinds of cancer cells and screen out the best compatibility of bufalin, Chinese toad, and bursaptin. The best compatibility comparison and verification test. Results: Compared with the control group, the inhibitory effects of A and B on lung cancer (H441) and cervical cancer cells (HeLa) were similar to those of mitomycin C (P> 0.05) Acting on mitomycin (P> 0.05). After multivariate statistical analysis, the best combination of Bufalin, Hua toad essence and resibufogenin was 100,100,15μmol·L -1. Conclusion: It is feasible to use the uniform design and in vitro anticancer evaluation to determine the best compatibility of three kinds of monomer in the toads, bufalin, bufalin and resibufogenin. Validation experiments show that Bufalin, Toad The best combination of detoxifier and lapatin was comparable to that of mitomycin in inhibiting cancer cells in vitro, slightly better than each monomer in the combination.